Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents
AssigneeKnoll, Inc.
InventorsKevin James Doyle, Frank Kerrigan, John Paul Watts
Life of this patent
Estimating the term…
Loading patent…
AssigneeKnoll, Inc.
InventorsKevin James Doyle, Frank Kerrigan, John Paul Watts
Estimating the term…
The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds of Formula (I) including pharmaceutically acceptable salts thereof in which have affinity for 5-HT1A receptors and which inhibits neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, as an aid to smoking cessation and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage.
A compound of Formula I
A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, as claimed in any previous claim, together with a pharmaceutically acceptable diluent or carrier.
The use of a compound which is a 5-HT1A agonist and which is also a monoamine reuptake inhibitor particularly a noradrenaline reuptake inhibitor in the treatment of obesity and related co-morbid conditions without causing cardiovascular side effects.
A method of treating obesity without causing cardiovascular side-effects comprising the administration of a compound which is a 5-HT1A agonist and which is also a monoamine reuptake inhibitor particularly a noradrenaline reuptake inhibitor.
Processes for the preparation of compounds of Formula I, as described herein.
Dependencies are inferred from the claim text.